Traditional laboratory software operates on predictable programmed conditions, but AI-driven tools introduce complexities that existing regulations struggle to contain. Unlike conventional systems where errors are systemic and easily traced, AI models may produce unpredictable, patient-specific inaccuracies. These models can generate unsupported information or shift behaviors unexpectedly following minor updates, creating safety gaps that the 1992-era CLIA standards were never designed to manage.
ADLM Presses for AI Regulatory Standards in Clinical Labs
The Association for Diagnostics & Laboratory Medicine is calling on federal regulators to integrate artificial intelligence under the existing Clinical Laboratory Improvement Amendments framework. The move comes as the group warns that current oversight fails to address the unique, case-specific risks posed by machine learning in modern diagnostics.
ADLM President Dr. Stanley F. Lo argues that innovation must not outpace patient safety. The association recommends a risk-based approach that keeps laboratory directors at the helm of validation while ensuring AI is treated as an integral part of the total testing process. By avoiding a separate, redundant regulatory structure, the group aims to leverage the expertise already present in clinical labs to monitor performance, validate results, and maintain high-quality diagnostic standards in an era of rapid technological adoption.
Comments (0)
No comments yet. Be the first!